Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Linical Co., Ltd. ( (JP:2183) ) has provided an update.
Linical Co., Ltd. reported a steep deterioration in results for the year ended March 31, 2026, with net sales falling 17% to ¥8.67 billion and the company posting an operating loss of ¥2.07 billion and a net loss of ¥3.33 billion. Profitability ratios turned deeply negative, shareholders’ equity shrank sharply, and cash and cash equivalents fell to ¥5.2 billion, reflecting pressure on its balance sheet.
The company halved its annual dividend to ¥8 per share for fiscal 2026 but plans to maintain that level in the year to March 2027, signaling a desire to continue shareholder returns despite losses. For the current fiscal year, Linical forecasts a recovery to ¥10.68 billion in sales and a return to modest profitability, with positive operating and ordinary income, indicating management’s expectation of operational improvement after two consecutive loss-making years.
More about Linical Co., Ltd.
Linical Co., Ltd. is a Japan-based contract research organization listed on the Tokyo Stock Exchange, providing clinical trial and related development services to pharmaceutical and biotechnology companies. The group operates globally and focuses on supporting drug development, which ties its performance closely to trends in R&D spending and project pipelines in the life sciences sector.
Average Trading Volume: 42,324
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen5.42B
See more insights into 2183 stock on TipRanks’ Stock Analysis page.